Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, July 27, 2023
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
[ Thu, Jul 27th 2023
] - WOPRAI
Andrew Fein Reiterated (AMLX) at Strong Buy and Held Target at $50 on, Jul 27th, 2023
Andrew Fein of HC Wainwright & Co., Reiterated "Amylyx Pharmaceuticals, Inc." (AMLX) at Strong Buy and Held Target at $50 on, Jul 27th, 2023.
Andrew has made no other calls on AMLX in the last 4 months.
There are 2 other peers that have a rating on AMLX. Out of the 2 peers that are also analyzing AMLX, 0 agree with Andrew's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Andrew
- Chris Shibutani of "Goldman Sachs" Upgraded from Hold to Strong Buy and Increased Target to $49 on, Monday, July 24th, 2023
- Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Decreased Target to $50 on, Monday, May 15th, 2023
